A 38-year-old man from Delhi with newly diagnosed pulmonary tuberculosis is started on standard first-line ATT (HRZE). After 2 months of treatment, sputum smear microscopy remains positive. Drug susceptibility testing (DST) is performed and reports resistance to both isoniazid and rifampicin. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has **multidrug-resistant TB (MDR-TB)** — resistance to both isoniazid (INH) and rifampicin (RIF), the two most potent first-line agents. Microbiological failure (persistent sputum positivity at 2 months) is a key indicator of drug resistance and mandates immediate regimen change. ## Management Algorithm for MDR-TB ```mermaid flowchart TD A[Suspected or confirmed MDR-TB]:::outcome --> B{DST confirms INH + RIF resistance?}:::decision B -->|Yes| C[Switch to WHO MDR-TB regimen]:::action C --> D[Intensive phase: 20 months total]:::action D --> E[Fluoroquinolone + Bedaquiline + Linezolid + Injectable]:::action E --> F[Sputum conversion & clinical improvement]:::outcome B -->|No| G[Continue first-line therapy]:::action ``` ## Key Point: MDR-TB Regimen **WHO-recommended MDR-TB regimen (2023 update):** - **Fluoroquinolone** (levofloxacin or moxifloxacin) — backbone of second-line therapy - **Bedaquiline** — ATP synthase inhibitor; critical for efficacy - **Linezolid** — oxazolidinone; excellent lung penetration - **Injectable agent** (amikacin or streptomycin) — for intensive phase - **Duration:** 20 months total (intensive phase 5–7 months, continuation phase 13–15 months) ## High-Yield: Microbiological Failure Definition **Sputum positivity at 2 months of standard ATT = microbiological failure** → implies drug resistance until proven otherwise. This is a **red flag** for MDR-TB and requires immediate DST and regimen change. ## Clinical Pearl: Why Not Add to Existing Regimen? Adding a single second-line drug to a failing first-line regimen (Option C) is **inadequate and promotes further resistance**. MDR-TB requires a **complete regimen change** with at least 4 drugs, including newer agents (bedaquiline, linezolid) to achieve cure. ## Rationale for Correct Answer Once DST confirms MDR-TB, the standard of care is **immediate switch to a WHO-recommended MDR-TB regimen**. Continuing first-line therapy or adding single agents will result in treatment failure and XDR-TB emergence. Imaging (CXR/CT) is useful for baseline assessment but should not delay initiation of appropriate second-line therapy. [cite:WHO TB Guidelines 2023, RNTCP Guidelines India]